Ernst Günther Carl has a total of 80 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Harninkontinenz nach radikaler Prostatektomie beim Prostatakarzinom – aktuelle Daten von 17.149 Patienten aus 125 zertifizierten Zentren

    by Christoph Kowalski, Nora Tabea Sibert, Peter Hammerer, Simone Wesselmann, Günter Feick, Ernst-Günther Carl, Theodor Klotz, Hendrik Apel, Sebastian Dieng, Joanne Nyarangi-Dix, et al.


  • Variation across operating sites in urinary and sexual outcomes after radical prostatectomy in localized and locally advanced prostate cancer

    by Nora Tabea Sibert, Holger Pfaff, Clara Breidenbach, Simone Wesselmann, Rebecca Roth, Günther Feick, Günter Carl, Sebastian Dieng, Amr A. Gaber, Andreas Blana, et al.

    Purpose The extent of variation in urinary and sexual functional outcomes after radical prostatectomy (RPE) between prostate cancer (PC) operating sites remains unknown. Therefore, this analysis aims to compare casemix-adjusted functional outcomes (EPIC-26 scores incontinence, irritative/obstructive function and sexual function) between operating sites 12 months after RPE. Materials and methods Analysis of a cohort of 7065 men treated with RPE at 88 operating sites (prostate cancer centers, “PCCs”) between 2016 and 2019. Patients completed EPIC-26 and sociodemographic information surveys at baseline and 12 months after RPE. Survey data were linked to clinical data. EPIC-26 domain scores at 12 months after RPE were adjusted for relevant confounders (including baseline domain score, clinical and sociodemographic information) using regression analysis. Differences between sites were described using minimal important differences (MIDs) and interquartile ranges (IQR). The effects of casemix adjustment on the score results were described using Cohen’s d and MIDs. Results Adjusted domain scores at 12 months varied between sites, with IQRs of 66–78 (incontinence), 89–92 (irritative/obstructive function), and 20–29 (sexual function). Changes in domain scores after casemix adjustment for sites ≥ 1 MID were noted for the incontinence domain (six sites). Cohen’s d ranged between − 0.07 (incontinence) and − 0.2 (sexual function), indicating a small to medium effect of casemix adjustment. Conclusions Variation between sites was greatest in the incontinence and sexual function domains for RPE patients. Future research will need to identify the factors contributing to this variation. Trial Registry. The study is registered at the German Clinical Trial Registry (https://www.drks.de/drks_web/) with the following ID: DRKS00010774.


  • Open Access

    PSMA-PET/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial

    by Constantinos Zamboglou, Simon K. B. Spohn, Sonja Adebahr, Maria Huber, Simon Kirste, Tanja Sprave, Christian Gratzke, Ronald C. Chen, Ernst Günther Carl, Wolfgang A. Weber, et al.

    Technical advances in radiotherapy (RT) treatment planning and delivery have substantially changed RT concepts for primary prostate cancer (PCa) by (i) enabling a reduction of treatment time, and by (ii) enabling safe delivery of high RT doses. Several studies proposed a dose–response relationship for patients with primary PCa and especially in patients with high-risk features, as dose escalation leads to improved tumor control. In parallel to the improvements in RT techniques, diagnostic imaging techniques like multiparametric magnetic resonance imaging (mpMRI) and positron-emission tomography targeting prostate-specific-membrane antigen (PSMA-PET) evolved and enable an accurate depiction of the intraprostatic tumor mass for the first time. The HypoFocal-SBRT study combines ultra-hypofractionated RT/stereotactic body RT, with focal RT dose escalation on intraprostatic tumor sides by applying state of the art diagnostic imaging and most modern RT concepts. This novel strategy will be compared with moderate hypofractionated RT (MHRT), one option for the curative primary treatment of PCa, which has been proven by several prospective trials and is recommended and carried out worldwide. We suspect an increase in relapse-free survival (RFS), and we will assess quality of life in order to detect potential changes.